Across TCGA pan-cancer cohorts, CYHR1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CYHR1 data layer compared with 22 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CYHR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYHR1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.
CCRCC, PDAC, and LUAD are the cancer types where CYHR1 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.